479 results about "Liver tissue" patented technology

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and / or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular / hepatic function and / or improving cardiovascular / hepatic disease or disorders.

The invention relates to the technical field of medical image information processing, discloses an ICG fluorescence image and MRCP three-dimensional model registration fusion display method and system, effectively solves the problems of deep biliary tract structure blurring and form distortion caused by liver tissue scattering effect in intraoperative fluorescence imaging, uses a preoperative model as anatomical prior, and improves the accuracy of the intraoperative fluorescence imaging. A viewpoint correlation optical path depth field is constructed through reverse ray tracing, a spatial variation point spread function is generated accordingly, physical reverse recovery of scattering halo in a fluorescence image is achieved, non-specific background noise such as vascular leakage is effectively inhibited in combination with topological gravitational constraint of a central skeleton, and the detection accuracy is improved. The real pipe diameter and the center line position of the deep bile duct are accurately recovered, non-rigid registration correction is performed on the three-dimensional model based on the recovered high-fidelity image, and projection errors caused by respiratory movement and soft tissue deformation are eliminated.

The invention relates to the technical field of temperature sensors, in particular to a temperature sensor dynamic response acceleration method and system for medical liver testing, and the method comprises the steps: collecting an original temperature measurement sequence outputted by a main temperature sensor in a first target region in real time, synchronously acquiring a reference temperature sequence output by a reference temperature sensor located in a second target area; and based on the physical characteristics of the main temperature sensor and the heat exchange characteristics of the liver tissue, constructing a sensor and liver tissue dynamic response model containing key dynamic parameter vectors. The dynamic response model of the sensor and the liver tissue is constructed, the dynamic characteristics of the sensor and the tissue in the current environment can be accurately quantified, thermal inertia and conduction delay are actively compensated from the algorithm level through the model inverse function, the real-time performance of temperature monitoring is remarkably improved, and the temperature monitoring accuracy is improved. And a timely and reliable feedback signal is provided for closed-loop control.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for improving acute alcoholic gastric mucosal lesion and application. The invention discloses the new medical application of the lucid ganoderma, ginseng and kudzuvine root formula for the first time, and experiments and clinical verifications prove that the formula can increase the activity of key enzymes in stomach and liver tissues of a mouse with acute alcoholic gastric mucosal injury, reduce the content of a proinflammatory factor TNF-alpha in the stomach tissues, increase the generation of an anti-inflammatory factor IL-10 in the stomach tissues, relieve the inflammatory injury of ethanol to gastric mucosa, improve the curative effect of alcohol on the gastric mucosa and improve the curative effect of alcohol on the gastric mucosa. The levels of protective factors EGF, SS and PGE-2 in serum are increased, the defense mechanism of gastric mucosa is enhanced, and the repairing capacity of the gastric mucosa is improved. The discovery has great influence on the research and treatment of acute alcoholic gastric mucosal injury diseases, and has clinical practical value.

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.

The invention relates to the technical field of molecular biology, gene therapy and drug development, and provides application of TRIM44 as a target in preparation of a drug for treating non-alcoholic fatty liver. The medicine prevents, relieves and / or treats the non-alcoholic fatty liver disease by inhibiting the expression level of TRIM44. According to the application disclosed by the invention, the TRIM44 is taken as a target, and the non-alcoholic fatty liver is prevented, relieved and treated by reducing the expression level of the TRIM44. The TRIM44 inhibitor enables the liver weight and the proportion of the liver in the body weight of a patient to be remarkably reduced, lipid accumulation to be reduced, fat deposition and vacuolation degree of liver tissue to be reduced and liver texture to be improved under poor diet conditions of high fat, high sugar and the like, so that the non-alcoholic fatty liver is prevented, relieved and treated, and the health state of the patient is improved.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The present invention relates to novel lipid nanoparticles capable of liver-specific delivery of mRNA, a manufacturing method therefor, and a liver disease therapeutic agent capable of regenerating the liver by liver-specific delivery of the bio-reprogramming factor mRNA using same. The lipid nanoparticles according to the present invention allow for liver-specific delivery of mRNA at very high efficiency, and the lipid nanoparticles that encapsulate the mRNA-based bio-reprogramming factor mRNA are specifically delivered to liver tissues of an individual requiring liver regeneration to induce short-term expression, thereby easily setting the dose and expression period of a therapeutic agent, leading to a significant reduction in side effects of a therapeutic agent for liver regeneration using an existing cell reprogramming factor.

The invention relates to a method for extracting high-purity extracellular vesicles from liver tissues of pelteobagrus vachelli, which comprises the following steps of: firstly, mixing collagenase II and collagenase IV, performing enzymolysis on the tissues, adding a CaCl2 solution, incubating, and digesting the liver tissues into a tissue suspension; then removing cells and fragments through low-speed centrifugation, and filtering to remove impurities by using needle filters of 0.8 [mu] m and 0.22 [mu] m; and finally, further purifying by combining ultracentrifugation with a high-precision iodixanol density gradient centrifugation method, and merging density layers with high purity to obtain high-purity EVs. The method has the characteristics of high extraction purity, high efficiency and simplicity and convenience in operation, and has a wide application prospect.

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention discloses an application of costunolide in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is found that costunolide can activate an Nrf2-ARE signal channel of a body, liver cell lipid metabolism abnormality is effectively improved from the molecular level, and meanwhile the pathological influence of oxidative damage on liver tissue is remarkably relieved. Experimental data show that the compound has a remarkable intervention effect on NAFLD, a scientific basis is provided for development of a novel liver disease treatment agent due to the unique dual regulation and control mechanism of the compound, particularly, the compound shows an important development prospect in the field of clinical intervention of metabolism-related liver injury, and an innovative solution is provided for NAFLD lacking a special-effect therapy at present.

The invention relates to a preparation method of exosome-like nano vesicles. The preparation method comprises the following steps: extracting beet juice; performing low-speed centrifugal treatment on the beet juice, and taking supernate; carrying out medium-speed centrifugation treatment on the supernatant obtained by low-speed centrifugation, and taking the supernatant; carrying out high-speed centrifugation treatment on the supernatant obtained by medium-speed centrifugation to obtain a precipitate containing exosome-like nano vesicles; and carrying out sucrose density gradient ultracentrifugation on the obtained precipitate containing the exosome-like nano-vesicles to obtain the purified exosome-like nano-vesicles. The BELNV prepared by the invention can significantly improve the survival rate of sepsis mice, increase blood perfusion of tissues and organs of the sepsis mice, reduce pathological changes, macrophage infiltration and fibrin deposition in lung and liver tissues of the sepsis mice, and reduce blood coagulation indexes and inflammation indexes. The invention provides a novel treatment target and strategy for a treatment means of sepsis-related blood coagulation dysfunction.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention discloses a construction and evaluation method of a liver injury organoid model, which comprises the following steps: (1) selecting mouse liver cells, perfusing a mouse with pancreatin through a sterile operation technology, removing blood in the liver, collecting liver tissues, and carrying out fine enzymolysis digestion treatment to obtain a single-cell suspension; (2) inoculating the single-cell suspension into a three-dimensional culture system, and carrying out preliminary stimulation by adopting a culture medium combined with growth factors and inhibition small molecules, so as to promote the growth, proliferation and differentiation of cells in a three-dimensional space; according to the cell growth condition, subculture operation is carried out in good time, so that continuous culture and amplification of liver organs are ensured; and (3) exposing the maturely cultured liver organoid in a stimulating factor for simulating a liver injury pathological environment, and constructing different types of liver injury organoid models. According to the liver injury organ-like model construction method, model construction can be completed in a short time, the research period is greatly shortened, the efficiency is high, and the cost is low.

The invention relates to the technical field of probiotics and application thereof, in particular to a plant lactobacillus ZKAW02 strain, a fungicide and application of the fungicide. The invention relates to a plant lactobacillus ZKAW02 strain, which is classified and named as plant lactobacillus, the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024, and the preservation number is GDMCC No: 65219. The invention further discloses a preparation method of the plant lactobacillus ZKAW02 strain. The plant lactobacillus ZKAW02 strain has the advantages that the plant lactobacillus ZKAW02 strain is named as plant lactobacillus, and the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024. The lactobacillus plantarum ZKAW02 has the effects of remarkably reducing the cholesterol level, remarkably regulating the blood fat level of the liver and excrement and remarkably increasing the short-chain fatty acid level in the excrement of a high-fat rat, so that the expression level of lipid metabolism related signal channel genes is regulated, the intestinal flora homeostasis is regulated, the liver tissue damage is repaired, and the anti-tumor effect is achieved. The effects of regulating lipid metabolism and intestinal health are achieved.

The invention discloses a liver protection composition containing glutathione-rich yeast. The liver protection composition is prepared from the glutathione-rich yeast, turmeric, silybum marianum, enzymolysis polypeptide with homology of medicine and food and anti-inflammatory and anti-oxidation auxiliary components. Wherein the medicine and food homologous enzymolysis polypeptide is prepared from radix puerariae through neutral protease-cellulase double enzymolysis, the polypeptide sequence is identified as Leuu-Val-Glu-Pro-Ala, and the medicine and food homologous enzymolysis polypeptide has the capacity of remarkably inhibiting LPS-induced RAW264.7 cell NO release and removing DPPH free radicals. According to the composition, through multi-component synergism, in an anti-alcohol experiment, the blood alcohol concentration decline rate of a mouse can be remarkably increased, the MDA content of liver tissue is remarkably reduced, and no acute toxic reaction exists. The composition has the functions of protecting the liver and dispelling the effects of alcohol, is safe and effective, and is suitable for the field of health-care products or functional foods.

The present invention provides novel capsid variants for viral vectors that simultaneously detarget liver tissue and efficiently transduce muscular tissue.

The application discloses a method for simulating a magnetic resonance signal of fatty liver tissue, which comprises the following five steps: obtaining a proton density fat fraction (PDFF) and an effective transverse relaxation rate parameter of the fatty liver tissue; and the method has the beneficial effects that: a three-dimensional simulation model of the fatty liver tissue with different fat fractions is simulated, the PDFF and the predicted value corresponding to the fat fraction are obtained, and thus a correction relationship between the fat fraction and the parameter is established; meanwhile, by adjusting the parameters (magnetic field strength, etc.) in the three-dimensional simulation model of the fatty liver tissue, the influence of fat on the parameter can be corrected in different scenes; and the method can improve the quantification accuracy of liver iron and liver fat through the correlation between the fat fraction and the parameter.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The invention discloses a composition for enhancing cold resistance based on pyroptosis regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method of the composition for enhancing cold resistance based on pyroptosis regulation comprises the following steps: S1, respectively preparing an angelica sinensis aqueous extract and an astragalus membranaceus aqueous extract; and S2, mixing the angelica sinensis aqueous extract and the astragalus membranaceus aqueous extract according to the mass ratio of 1: (4-20) to obtain the composition for enhancing cold resistance based on pyroptosis regulation. The invention further provides a composition obtained based on the preparation method, a preparation and application. The composition provided by the invention can significantly prolong the survival time of acute cold exposure mice; the core body temperature of an acute cold exposure mouse is obviously improved, liver injury is relieved, and liver tissue cell pyroptosis pathway protein expression is regulated.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The invention provides a construction method of an animal model of chronic low-dose cadmium exposure induced hepatic fibrosis, and provides a research basis for the reason of chronic cadmium exposure induced hepatic fibrosis and the drug efficacy analysis of the chronic cadmium exposure induced hepatic fibrosis. The method simulates a chronic low-dose cadmium exposure condition, is convenient to operate and stable, can help scientific researchers to visually observe the occurrence and development process of chronic liver injury and hepatic fibrosis induced by heavy metal exposure, and can provide a powerful basis for mechanism research of heavy metal poisoning. According to experimental results, in the body shape, living state, liver appearance and liver tissue pathological change process of a mouse, the mouse shows the mouse liver chronic injury and fibrosis change process under the chronic low-dose cadmium exposure environment, the direct relation between the cadmium exposure time and the liver fibrosis progress can be directly obtained, and the obtained animal model is stable. Researchers can create a disease process similar to human diseases through construction of the animal model in the future, the disease process can be quickly simulated, mass copying can be performed in a short time, the research period can be shortened, the animal model can be used for large-scale experimental research, and powerful support is provided for drug research and development and treatment strategies.

The invention relates to an immune Raman multicolor imaging kit for liver cancer prediction and evaluation, the immune Raman multicolor imaging kit comprises five Raman probes, and the Raman probes are composed of Raman balls and antibodies connected to the surfaces of the Raman balls; wherein the Raman sphere is formed by polymerizing a triple bond monomer and (i) acrylic acid or (ii) styrene and acrylic acid, the particle size is 10-100 nm, and the Raman shift is 1800-2800 cm <-1 >; antibodies of the five Raman probes are respectively selected from one of an AFP antibody, an HBX antibody, a GPC3 antibody, a GS antibody and a CD34 antibody. The immune Raman multicolor imaging reagent and kit provided by the invention can realize one-step marking and multiple color development of five liver cancer related protein markers in the same liver tissue slice. Compared with a multiple fluorescence immunohistochemical technology, the method has remarkable advantages in efficiency and precision. Experiments show that the detection result is consistent with the clinical diagnosis result, and the application potential is huge.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The invention discloses application of phloretin in preparation of a medicine for promoting liver cell proliferation, and belongs to the technical field of medicine. A specific cell proliferation tracing system of the hepatocytes is utilized, the proliferation activity of the hepatocytes in an animal body can be continuously recorded, animal experiments find that in the physiological homeostasis maintaining process of a mouse, phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of liver tissue, and it is found through hepatic lobule zoning analysis that phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of the liver tissue. The phloretin can effectively promote proliferation of hepatic cells in the first, second and third regions of the hepatic lobule. Therefore, phloretin is a potential medicine for liver regeneration.

The invention belongs to the technical field of bioengineering, particularly relates to the field of tumor animal model research, and particularly provides a primary in-situ hepatocellular carcinoma animal model and a construction method thereof, and the primary in-situ hepatocellular carcinoma animal model is characterized in that primary in-situ hepatocellular carcinoma is formed in an animal liver; the primary in-situ hepatocellular carcinoma is formed in a primary in-situ manner by introducing a gene-edited liver organ into an animal liver tissue. The innovative hepatocellular carcinoma model construction technology promotes the primary in-situ development of long liver organs after gene editing into hepatocellular carcinoma, not only is the preparation period shorter, but also the tumor formation efficiency is higher, the occurrence and development, pathological conditions and clinical drug response of liver cancer patients can be effectively simulated, the full simulation of the tumor microenvironment is realized, and the application prospect is wide. And the development and research of new drugs and new treatment methods can be better guided.

The invention relates to the technical field of image segmentation, in particular to an automatic real-time outline drawing system for a liver tumor ablation area based on an ultrasonic image. The method comprises the following steps: firstly, registering and aligning preoperative and intraoperative ultrasonic images, and eliminating displacement deviation caused by factors such as respiratory movement and probe shaking; further based on the essential difference between the ablation region and the surrounding normal liver tissue in ultrasonic echo expression, dynamic changes of region features are analyzed to obtain ablation feature parameters of each sub-region in the intraoperative ultrasonic image so as to evaluate the ablation state, and then the image is enhanced based on the ablation state so as to enhance the boundary definition, and finally the ablation state of the intraoperative ultrasonic image is evaluated. And the outline drawing accuracy of the outline of the liver tumor ablation area is improved.